$ELTX
Elicio Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000160148524000075 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $7.208M
YoY Change -0.77%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $7.208M
YoY Change -0.77%
Operating Profit -$10.34M
YoY Change -3.96%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$8.494M
YoY Change -7616.81%
Pretax Income
YoY Change
Income Tax $0.00
% Of Pretax Income
Net Earnings -$18.84M
YoY Change 76.75%
Net Earnings / Revenue
Basic Earnings Per Share -$1.39
Diluted Earnings Per Share -$1.39
COMMON SHARES
Basic Shares Outstanding 10.79M shares 10.77M shares
Diluted Shares Outstanding 13.58M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $26.02M
YoY Change 75.78%
Cash & Equivalents $26.00M
Short-Term Investments
Other Short-Term Assets $4.628M
YoY Change -7.44%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $30.65M
YoY Change 53.76%
LONG-TERM ASSETS
Property, Plant & Equipment $523.0K
YoY Change -32.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.293M
YoY Change -63.06%
Total Long-Term Assets $7.742M
YoY Change -29.97%
TOTAL ASSETS
Total Short-Term Assets $30.65M
Total Long-Term Assets $7.742M
Total Assets $38.39M
YoY Change 23.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.984M
YoY Change -54.97%
Accrued Expenses $4.852M
YoY Change 9.87%
Deferred Revenue $1.307M
YoY Change -21.45%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.020M
YoY Change -21.47%
LONG-TERM LIABILITIES
Long-Term Debt $19.84M
YoY Change
Other Long-Term Liabilities $28.52M
YoY Change 359.98%
Total Long-Term Liabilities $48.35M
YoY Change 679.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.020M
Total Long-Term Liabilities $48.35M
Total Liabilities $57.37M
YoY Change 224.13%
SHAREHOLDERS EQUITY
Retained Earnings -$180.1M
YoY Change 35.11%
Common Stock $108.0K
YoY Change 28.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$18.99M
YoY Change
Total Liabilities & Shareholders Equity $38.39M
YoY Change 23.88%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$18.84M
YoY Change 76.75%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$7.274M
YoY Change 40.15%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.75M
YoY Change 51156.67%
NET CHANGE
Cash From Operating Activities -7.274M
Cash From Investing Activities 0.000
Cash From Financing Activities 30.75M
Net Change In Cash 23.48M
YoY Change -554.16%
FREE CASH FLOW
Cash From Operating Activities -$7.274M
Capital Expenditures $0.00
Free Cash Flow -$7.274M
YoY Change 38.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10798832 shares
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22947000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17692000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3136000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3507000 usd
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
10344000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
10771000 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01
dei Trading Symbol
TradingSymbol
ELTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q4 us-gaap Prepaid Expense Other Noncurrent
PrepaidExpenseOtherNoncurrent
2833000 usd
CY2024Q3 us-gaap Assets
Assets
38388000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1984000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4369000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4852000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3757000 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1307000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
694000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
877000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
910000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
9020000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9755000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.75
dei Entity Registrant Name
EntityRegistrantName
Elicio Therapeutics, Inc.
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
1318000 usd
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
722000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3312000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2732000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
30646000 usd
CY2024Q3 us-gaap Prepaid Expense Other Noncurrent
PrepaidExpenseOtherNoncurrent
600000 usd
CY2023Q4 us-gaap Assets
Assets
27146000 usd
CY2024Q3 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
0 usd
CY2023Q4 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
25000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
57374000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
15773000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7559000 usd
CY2023Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2023Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
23557000 usd
us-gaap Depreciation
Depreciation
302000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
582000 usd
angn Interest Expense Noncash
InterestExpenseNoncash
1060000 usd
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
0 usd
dei Entity File Number
EntityFileNumber
001-39990
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
107000 usd
us-gaap Net Income Loss
NetIncomeLoss
-37894000 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
36000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-18838000 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001601485
dei Amendment Flag
AmendmentFlag
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-3430072
dei Entity Address Address Line1
EntityAddressAddressLine1
451 D Street, 5th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02210
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
209-0050
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10791326 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26016000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12894000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
16348000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
523000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
717000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5926000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6563000 usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
693000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
685000 usd
CY2023Q4 angn Warrant Liability
WarrantLiability
11000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5338000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6007000 usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7208000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7264000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10344000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10771000 usd
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5617000 usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6000 usd
CY2024Q3 angn Gain Loss On Issuance Of Warrants
GainLossOnIssuanceOfWarrants
-2924000 usd
CY2023Q3 angn Gain Loss On Issuance Of Warrants
GainLossOnIssuanceOfWarrants
0 usd
CY2024Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2024Q3 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0 usd
CY2023Q3 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-105000 usd
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1000 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-33000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
246000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
137000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8494000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
113000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-18838000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10658000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18802000 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.39
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.39
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.27
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.27
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13582345 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13582345 shares
CY2024Q3 angn Warrant Liability
WarrantLiability
23181000 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9618178 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10784377 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9603723 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
108000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
96000 usd
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
14455 shares
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
14455 shares
CY2024Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
150000 usd
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
150000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
161355000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
153827000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-202000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-197000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-180097000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-142203000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-18986000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11373000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38388000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27146000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8563000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8661000 usd
us-gaap Costs And Expenses
CostsAndExpenses
31510000 usd
us-gaap Costs And Expenses
CostsAndExpenses
26353000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-31510000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-26353000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3279000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
17000 usd
angn Gain Loss On Issuance Of Warrants
GainLossOnIssuanceOfWarrants
-3502000 usd
angn Gain Loss On Issuance Of Warrants
GainLossOnIssuanceOfWarrants
0 usd
CY2024Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
429000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
604000 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
3000 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-105000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
143000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-45000 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
185000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
472000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
298000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
221000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1057000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6384000 usd
us-gaap Net Income Loss
NetIncomeLoss
-26246000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-23000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-5000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-25000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10681000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37899000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26271000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.75
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8376384 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8376384 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11720527 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11720527 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3894073 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3894073 shares
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11373000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
103000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5062000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
11000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
324000 usd
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-73000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-11827000 usd
CY2024Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2024Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
4870000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
9000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
6000 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
303000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
350000 usd
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
32000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7229000 usd
CY2024Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2024Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-1652000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
5000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
314000 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
36000 usd
CY2024Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2024Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-18986000 usd
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
4997920 shares
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
111060000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-102145000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
40000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
34000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
224000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-8029000 usd
CY2023Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
4997920 shares
CY2023Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
111060000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-109876000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
11000 usd
CY2023Q2 angn Temporary Equity Stock Issued During Period Shares New Issues
TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
4997920 shares
CY2023Q2 us-gaap Temporary Equity Stock Issued During Period Value New Issues
TemporaryEquityStockIssuedDuringPeriodValueNewIssues
111060000 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2400000 usd
CY2023Q2 angn Stock Issued During Period Value Reverse Recapitalization
StockIssuedDuringPeriodValueReverseRecapitalization
19739000 usd
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
150000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
279000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
60000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
11000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
339000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-23000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10658000 usd
CY2023Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2023Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
13286000 usd
us-gaap Net Income Loss
NetIncomeLoss
-37894000 usd
us-gaap Net Income Loss
NetIncomeLoss
-26246000 usd
us-gaap Depreciation
Depreciation
236000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
637000 usd
angn Interest Expense Noncash
InterestExpenseNoncash
82000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
26000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
429000 usd
angn Costs Expensed Upon The Issuance Of Warrants
CostsExpensedUponTheIssuanceOfWarrants
549000 usd
angn Costs Expensed Upon The Issuance Of Warrants
CostsExpensedUponTheIssuanceOfWarrants
0 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3279000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
17000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
988000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
842000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
604000 usd
angn Gain Loss On Issuance Of Warrants
GainLossOnIssuanceOfWarrants
-3502000 usd
angn Gain Loss On Issuance Of Warrants
GainLossOnIssuanceOfWarrants
0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
3000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-105000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
580000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
41000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-2233000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2385000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
63000 usd
angn Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
1095000 usd
angn Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
1910000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
613000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
228000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-702000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-588000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28324000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22799000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
66000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
34000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-39000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-32000 usd
us-gaap Cash Acquired In Excess Of Payments To Acquire Business
CashAcquiredInExcessOfPaymentsToAcquireBusiness
0 usd
us-gaap Cash Acquired In Excess Of Payments To Acquire Business
CashAcquiredInExcessOfPaymentsToAcquireBusiness
24001000 usd
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
0 usd
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
2366000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10000000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
19727000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
17469000 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 usd
angn Payment Of Warrant Issuance Costs
PaymentOfWarrantIssuanceCosts
549000 usd
angn Payment Of Warrant Issuance Costs
PaymentOfWarrantIssuanceCosts
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5413000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
0 usd
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
150000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
34000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
127000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42094000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31612000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13726000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8781000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14301000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8414000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28027000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17195000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26016000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14841000 usd
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2011000 usd
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2354000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28027000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17195000 usd
angn Fair Value Of Pre Funded Warrants
FairValueOfPreFundedWarrants
13382000 usd
angn Fair Value Of Pre Funded Warrants
FairValueOfPreFundedWarrants
0 usd
angn Fair Value Of Common Stock Warrants
FairValueOfCommonStockWarrants
6509000 usd
angn Fair Value Of Common Stock Warrants
FairValueOfCommonStockWarrants
0 usd
angn Accretion Of Convertible Notes Discount From Issuance Costs
AccretionOfConvertibleNotesDiscountFromIssuanceCosts
26000 usd
angn Accretion Of Convertible Notes Discount From Issuance Costs
AccretionOfConvertibleNotesDiscountFromIssuanceCosts
130000 usd
angn Accretion Of Promissory Note To Face Value
AccretionOfPromissoryNoteToFaceValue
0 usd
angn Accretion Of Promissory Note To Face Value
AccretionOfPromissoryNoteToFaceValue
897000 usd
angn Non Cash Vesting Of Restricted Common Stock
NonCashVestingOfRestrictedCommonStock
25000 usd
angn Non Cash Vesting Of Restricted Common Stock
NonCashVestingOfRestrictedCommonStock
67000 usd
angn Settlement Of Promissory Notes Payable
SettlementOfPromissoryNotesPayable
0 usd
angn Settlement Of Promissory Notes Payable
SettlementOfPromissoryNotesPayable
10028000 usd
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9700000 shares
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-180100000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26000000.0 usd
CY2023Q2 angn Recapitalization Exchange Ratio
RecapitalizationExchangeRatio
0.0181
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Financial Statement Reclassification</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain account balances from prior periods have been reclassified in these condensed consolidated financial statements to conform to current period classifications. The warrant liability was reclassified from current to noncurrent liabilities. These reclassifications had no effect on the reported results of operations or financial position.</span></div>
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.75
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3894073 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3894073 shares
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Use of Estimates</span></div>The Company’s management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates. Significant estimates reflected in these condensed consolidated financial statements include but are not limited to, the accrual of research and development expenses, the valuation of stock-based awards, the valuation of warrants, the valuation of embedded derivatives and convertible debt, the operating lease right-of-use assets and operating lease liability, and forecasts utilized in management’s going concern assessment.
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div>Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and restricted cash. At times, cash balances deposited at major financial banking institutions exceed the federally insured limit. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal. The Company has not experienced any losses in such accounts.
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2023Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2024Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2024Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2023Q2 angn Number Of Members Of The Board Of Directors
NumberOfMembersOfTheBoardOfDirectors
9 board_member
CY2023Q2 angn Recapitalization Exchange Ratio
RecapitalizationExchangeRatio
0.0181
CY2023Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
5375751 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8387025 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8387025 shares
CY2023Q2 angn Cash And Cash Equivalents Acquired Through Reverse Recapitalization
CashAndCashEquivalentsAcquiredThroughReverseRecapitalization
24001000 usd
CY2023Q2 angn Other Current Assets Acquired Through Reverse Recapitalization
OtherCurrentAssetsAcquiredThroughReverseRecapitalization
540000 usd
CY2023Q2 angn Promissory Notes Acquired Through Reverse Recapitalization
PromissoryNotesAcquiredThroughReverseRecapitalization
10027000 usd
CY2023Q2 angn Accrued Liabilities Assumed Through Reverse Recapitalization
AccruedLiabilitiesAssumedThroughReverseRecapitalization
2438000 usd
CY2023Q2 angn Net Assets Acquired Through Reverse Recapitalization
NetAssetsAcquiredThroughReverseRecapitalization
32130000 usd
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
600000 usd
angn Reverse Recapitalization Transaction Costs
ReverseRecapitalizationTransactionCosts
2900000 usd
CY2024Q3 angn Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
2573000 usd
CY2023Q4 angn Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
1883000 usd
CY2024Q3 angn Advanced Professional Fees
AdvancedProfessionalFees
230000 usd
CY2023Q4 angn Advanced Professional Fees
AdvancedProfessionalFees
300000 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
453000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
376000 usd
CY2024Q3 angn Miscellaneous Receivables
MiscellaneousReceivables
2000 usd
CY2023Q4 angn Miscellaneous Receivables
MiscellaneousReceivables
0 usd
CY2024Q3 angn Other Prepaid Expenses And Other Assets Current
OtherPrepaidExpensesAndOtherAssetsCurrent
54000 usd
CY2023Q4 angn Other Prepaid Expenses And Other Assets Current
OtherPrepaidExpensesAndOtherAssetsCurrent
173000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3312000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2732000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1990000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1948000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1467000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1231000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
523000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
717000 usd
CY2024Q3 us-gaap Depreciation
Depreciation
0 usd
us-gaap Depreciation
Depreciation
200000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
0 usd
us-gaap Depreciation
Depreciation
300000 usd
CY2024Q3 us-gaap Prepaid Expense Other Noncurrent
PrepaidExpenseOtherNoncurrent
600000 usd
CY2023Q4 us-gaap Prepaid Expense Other Noncurrent
PrepaidExpenseOtherNoncurrent
2800000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
972000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
945000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1472000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1849000 usd
CY2024Q3 angn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2395000 usd
CY2023Q4 angn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
912000 usd
CY2024Q3 angn Accrued Other Operating Liabilities Current
AccruedOtherOperatingLiabilitiesCurrent
13000 usd
CY2023Q4 angn Accrued Other Operating Liabilities Current
AccruedOtherOperatingLiabilitiesCurrent
51000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4852000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3757000 usd
CY2024Q3 angn Number Of Research Grant Agreements
NumberOfResearchGrantAgreements
3 agreement
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1305924 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
21.27
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M4D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2511000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
764334 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.67
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
8744 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
200560 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.56
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1860954 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.87
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M8D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
833000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
819302 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
29.44
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y11M19D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
364000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
764334 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.67
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3500000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y5M4D
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
314000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
339000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
988000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
842000 usd
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
148764 shares
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
54.19
CY2023Q4 angn Class Of Warrant Or Right Weighted Average Life
ClassOfWarrantOrRightWeightedAverageLife
P5Y6M
angn Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
5132702 shares
angn Class Of Warrant Or Right Weighted Average Exercise Price Issued In Period
ClassOfWarrantOrRightWeightedAverageExercisePriceIssuedInPeriod
2.25
angn Class Of Warrant Or Right Exercised In Period
ClassOfWarrantOrRightExercisedInPeriod
0 shares
angn Class Of Warrant Or Right Weighted Average Exercise Price Exercises In Period
ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5281466 shares
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.71
CY2024Q3 angn Class Of Warrant Or Right Weighted Average Life
ClassOfWarrantOrRightWeightedAverageLife
P4Y9M18D
angn License Expense
LicenseExpense
300000 usd
CY2024Q3 angn Operating Lease Future Minimum Annual Maintenance Payments Due Each Fiscal Year
OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueEachFiscalYear
100000 usd
CY2024Q3 angn Operating Lease Future Minimum Annual Maintenance Payments Due Remainder Of Fiscal Year
OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueRemainderOfFiscalYear
100000 usd
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1100000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1100000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1096000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1002000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y3M29D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y2M12D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.077
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
331000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1350000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1383000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1425000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1467000 usd
CY2024Q3 angn Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1765000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7721000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1506000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
6215000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
877000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5338000 usd
CY2024Q3 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
19700000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-18838000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10658000 usd
us-gaap Net Income Loss
NetIncomeLoss
-37894000 usd
us-gaap Net Income Loss
NetIncomeLoss
-26246000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13582345 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13582345 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8376384 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8376384 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11720527 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11720527 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3894073 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3894073 shares
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.39
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.39
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.27
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.75
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3268071 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1462534 shares
CY2024Q3 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
19700000 usd
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
angn-20240930_cal.xml Edgar Link unprocessable
0001601485-24-000075-index-headers.html Edgar Link pending
0001601485-24-000075-index.html Edgar Link pending
0001601485-24-000075.txt Edgar Link pending
0001601485-24-000075-xbrl.zip Edgar Link pending
angn-20240930.htm Edgar Link pending
angn-20240930.xsd Edgar Link pending
ex101elicio-securitiespu.htm Edgar Link pending
ex101elicio-securitiespu001.jpg Edgar Link pending
ex101elicio-securitiespu002.jpg Edgar Link pending
ex101elicio-securitiespu003.jpg Edgar Link pending
ex101elicio-securitiespu004.jpg Edgar Link pending
ex101elicio-securitiespu005.jpg Edgar Link pending
ex101elicio-securitiespu006.jpg Edgar Link pending
ex101elicio-securitiespu007.jpg Edgar Link pending
ex101elicio-securitiespu008.jpg Edgar Link pending
ex101elicio-securitiespu009.jpg Edgar Link pending
ex101elicio-securitiespu010.jpg Edgar Link pending
ex101elicio-securitiespu011.jpg Edgar Link pending
ex101elicio-securitiespu012.jpg Edgar Link pending
ex101elicio-securitiespu013.jpg Edgar Link pending
ex101elicio-securitiespu014.jpg Edgar Link pending
ex101elicio-securitiespu015.jpg Edgar Link pending
ex101elicio-securitiespu016.jpg Edgar Link pending
ex101elicio-securitiespu017.jpg Edgar Link pending
ex101elicio-securitiespu018.jpg Edgar Link pending
ex101elicio-securitiespu019.jpg Edgar Link pending
ex101elicio-securitiespu020.jpg Edgar Link pending
ex101elicio-securitiespu021.jpg Edgar Link pending
ex101elicio-securitiespu022.jpg Edgar Link pending
ex101elicio-securitiespu023.jpg Edgar Link pending
ex101elicio-securitiespu024.jpg Edgar Link pending
ex101elicio-securitiespu025.jpg Edgar Link pending
ex101elicio-securitiespu026.jpg Edgar Link pending
angn-20240930_def.xml Edgar Link unprocessable
angn-20240930_pre.xml Edgar Link unprocessable
angn-20240930_lab.xml Edgar Link unprocessable
angn-20240930_htm.xml Edgar Link completed
ex101elicio-securitiespu027.jpg Edgar Link pending
ex101elicio-securitiespu028.jpg Edgar Link pending
ex101elicio-securitiespu029.jpg Edgar Link pending
ex101elicio-securitiespu030.jpg Edgar Link pending
ex101elicio-securitiespu031.jpg Edgar Link pending
ex101elicio-securitiespu032.jpg Edgar Link pending
ex101elicio-securitiespu033.jpg Edgar Link pending
ex101elicio-securitiespu034.jpg Edgar Link pending
ex101elicio-securitiespu035.jpg Edgar Link pending
ex101elicio-securitiespu036.jpg Edgar Link pending
ex101elicio-securitiespu037.jpg Edgar Link pending
ex101elicio-securitiespu038.jpg Edgar Link pending
ex101elicio-securitiespu039.jpg Edgar Link pending
ex101elicio-securitiespu040.jpg Edgar Link pending
ex101elicio-securitiespu041.jpg Edgar Link pending
ex102elicio-securityagre.htm Edgar Link pending
ex102elicio-securityagre001.jpg Edgar Link pending
ex102elicio-securityagre002.jpg Edgar Link pending
ex102elicio-securityagre003.jpg Edgar Link pending
ex102elicio-securityagre004.jpg Edgar Link pending
ex102elicio-securityagre005.jpg Edgar Link pending
ex102elicio-securityagre006.jpg Edgar Link pending
ex102elicio-securityagre007.jpg Edgar Link pending
ex102elicio-securityagre008.jpg Edgar Link pending
ex102elicio-securityagre009.jpg Edgar Link pending
ex102elicio-securityagre010.jpg Edgar Link pending
ex103elicio-ipsecurityag.htm Edgar Link pending
ex103elicio-ipsecurityag001.jpg Edgar Link pending
ex103elicio-ipsecurityag002.jpg Edgar Link pending
ex103elicio-ipsecurityag003.jpg Edgar Link pending
ex103elicio-ipsecurityag004.jpg Edgar Link pending
ex103elicio-ipsecurityag005.jpg Edgar Link pending
ex103elicio-ipsecurityag006.jpg Edgar Link pending
ex103elicio-ipsecurityag007.jpg Edgar Link pending
ex103elicio-ipsecurityag008.jpg Edgar Link pending
ex103elicio-ipsecurityag009.jpg Edgar Link pending
ex104elicio-subsidiarygu.htm Edgar Link pending
ex104elicio-subsidiarygu001.jpg Edgar Link pending
ex104elicio-subsidiarygu002.jpg Edgar Link pending
ex104elicio-subsidiarygu003.jpg Edgar Link pending
ex104elicio-subsidiarygu004.jpg Edgar Link pending
ex104elicio-subsidiarygu005.jpg Edgar Link pending
ex104elicio-subsidiarygu006.jpg Edgar Link pending
ex104elicio-subsidiarygu007.jpg Edgar Link pending
ex104elicio-subsidiarygu008.jpg Edgar Link pending
ex104elicio-subsidiarygu009.jpg Edgar Link pending
ex311_eltx-09302024x10xq.htm Edgar Link pending
ex321eltx-09302024x10xq.htm Edgar Link pending
ex41elicio-gkccpromissor.htm Edgar Link pending
ex41elicio-gkccpromissor001.jpg Edgar Link pending
ex41elicio-gkccpromissor002.jpg Edgar Link pending
ex41elicio-gkccpromissor003.jpg Edgar Link pending
ex41elicio-gkccpromissor004.jpg Edgar Link pending
ex41elicio-gkccpromissor005.jpg Edgar Link pending
ex41elicio-gkccpromissor006.jpg Edgar Link pending
ex41elicio-gkccpromissor007.jpg Edgar Link pending
ex41elicio-gkccpromissor008.jpg Edgar Link pending
ex41elicio-gkccpromissor009.jpg Edgar Link pending
ex41elicio-gkccpromissor010.jpg Edgar Link pending
ex41elicio-gkccpromissor011.jpg Edgar Link pending
ex41elicio-gkccpromissor012.jpg Edgar Link pending
ex41elicio-gkccpromissor013.jpg Edgar Link pending
ex41elicio-gkccpromissor014.jpg Edgar Link pending
ex41elicio-gkccpromissor015.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable